文献速递前列腺癌

主动监测中双侧病变与前列腺癌进展风险:MRI融合联合系统活检的意义

The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy.
PubMed 文献 · J Urol · 2021-06-28

该研究基于2007-2020年前列腺癌主动监测(AS)队列,纳入103例确认性联合活检(Cbx)为GG1且随访≥1年的患者。发现双侧病变和PSA密度与进展至≥GG2风险独立相关,Cbx较系统活检(Sbx)多检出16%的双侧病变。

要点

  • 确认性活检双侧病变与AS进展至≥GG2风险独立相关(HR 2.21)。
  • PSA密度也是AS进展的独立预测因素(HR 1.72)。
  • 联合活检(Cbx)比单纯系统活检(Sbx)多检出16%的双侧病变。

核心结论

  • 确认性联合活检发现双侧病变和PSA密度升高与AS患者更早进展至≥GG2相关。
  • 联合活检在识别双侧病变方面优于单纯系统活检。

研究设计与样本

  • 回顾性分析2007-2020年前瞻性维护数据库,纳入103例确认性Cbx为GG1且随访≥1年的AS患者。

主要发现

  • 49/103(47.6%)患者进展至≥GG2,单侧病变进展30/72(41.7%),双侧病变进展19/31(61.3%)。
  • 单侧与双侧病变的中位进展时间分别为68个月和52个月(p=0.006)。
  • Cox分析显示PSA密度(HR 1.72,p=0.005)和双侧病变(HR 2.21,p=0.012)与AS进展相关。
  • 进展时双侧病变患者的GG和风险分组显著高于单侧病变患者。
  • Cbx比单纯Sbx多检出16%的双侧病变患者。

临床怎么用

  • AS风险分层方案可考虑纳入双侧病变。
  • 应采用联合活检(Cbx)来检测双侧病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to evaluate whether bilateral prostate cancer detected at active surveillance (AS) enrollment is associated with progression to Grade Group (GG) ≥2 and to compare the efficacy of combined targeted biopsy plus systematic biopsy (Cbx) vs systematic biopsy (Sbx) or targeted biopsy alone to detect bilateral disease. MATERIALS AND METHODS: A prospectively maintained database of patients referred to our institution from 2007-2020 was queried. The study cohort included all AS patients with GG1 on confirmatory Cbx and followup of at least 1 year. Cox proportional hazard analysis identified baseline characteristics associated with progression to ≥GG2 at any point throughout followup. RESULTS: Of 579 patients referred, 103 patients had GG1 on Cbx and were included in the study; 49/103 (47.6%) patients progressed to ≥GG2, with 30/72 (41.7%) patients with unilateral disease progressing and 19/31 (61.3%) patients with bilateral disease progressing. Median time to progression was 68 months vs 52 months for unilateral and bilateral disease, respectively (p=0.006). Both prostate specific antigen density (HR 1.72, p=0.005) and presence of bilateral disease (HR 2.21, p=0.012) on confirmatory biopsy were associated with AS progression. At time of progression, GG and risk group were significantly higher in patients with bilateral versus unilateral disease. Cbx detected 16% more patients with bilateral disease than Sbx alone. CONCLUSIONS: Bilateral disease and prostate specific antigen density at confirmatory Cbx conferred greater risk of earlier AS progression. Cbx was superior to Sbx for identifying bilateral disease. AS risk-stratification protocols may benefit from including presence of bilateral disease and should use Cbx to detect bilateral disease.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Williams C, Khondakar NR, Daneshvar MA, et al. The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy. J Urol. 2021. PMID: 34181465. doi:10.1097/JU.0000000000001941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。